0.10Open0.13Pre Close145 Volume766 Open Interest5.50Strike Price1.55KTurnover155.08%IV10.59%PremiumMay 2, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.3085Delta0.5200Gamma40.80Leverage Ratio-0.0479Theta0.0001Rho12.59Eff Leverage0.0015Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet